Peptide library / IGF-1 DES

IGF-1 DES

IGF-1 DES is a truncated insulin-like growth factor 1 analog lacking the first three amino acids; it is distinct from native IGF-1, mecasermin and IGF-1 LR3.

Peptide & blend guide

The short version

Why people discuss it
Discussed for muscle growth and training-related recovery; DES differs from LR3 and mecasermin. Community interest does not establish benefit or a suitable treatment.
What it is
IGF-1 DES is a truncated insulin-like growth factor 1 analog lacking the first three amino acids; it is distinct from native IGF-1, mecasermin and IGF-1 LR3.
Biggest caution
Native IGF-1, mecasermin and LR3 evidence cannot supply efficacy, dosing or safety conclusions for DES. Product identity and local versus systemic effects require separate evidence.
Stack context
Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.

Dose and frequency reference

Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.

Source agreement describes reported practice, not clinical validation.

Intramuscular or subcutaneous injection

Community reference · Not clinical guidance
Amount
20–50 mcg
Frequency
Once daily on training days
Duration / phase
4 weeks

Community pattern without human dose-finding The new inbox sources do not independently corroborate this complete regimen. Reference only; this does not establish safety, effectiveness or individual suitability.

Reference source · reviewed 2026-09-12
Compare reported schedules

Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.

Evidence & sources · Community source profile

AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.

Back to the peptide library